Lipocine Inc.
LPCNHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Lipocine Inc. focuses on Biotechnology services and products. Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. At a $20.2M market cap, Lipocine Inc. ranks as a micro-cap company within healthcare. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Market Cap
$20.2M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-1.98
EPS (TTM)
$-1.85
EPS (Fwd)
$-1.24
ROE
-60.9%
ROA
-37.0%
Cash
$23.3M
Total Debt
$257,807
Free CF
-$6.9M
52W Change
-14.5%
Annual Financials
Cash vs Debt
Where LPCN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LPCN finished 42.12% below its 150-day moving average ($4.06) and 47.89% below its 200-day moving average ($4.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LPCN overbought or oversold?
At the September 3, 2026 close, LPCN's RSI(14) was 74.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lipocine Inc. holds $23.3M in cash against $258K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -60.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $500K to $2.0M.
The relatively low beta of 0.47 suggests LPCN is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing LPCN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.